We are also interested in the effect of Sparcl1 fusion on known aggregation-prone proteins in the field of neurodegenerative diseases, such as amyloid β in Alzheimer’s disease, α-synuclein in Parkinson’s disease, huntingtin protein in Huntington’s disease, and SOD1 in amyotrophic lateral sclerosis. Here, SPARCL1 is linked to early-onset autosomal dominant Alzheimer disease.